Can a new injection outperform semaglutide for diabetes remission?

NCT ID NCT07743983

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial is testing whether an experimental drug called BGM0504 can help people with early-stage type 2 diabetes and obesity achieve better blood sugar control and weight loss than a standard treatment, semaglutide. Participants will receive either BGM0504 or semaglutide as a once-weekly injection for 52 weeks. The study will measure how many people reach a combined goal of lower blood sugar and significant weight loss, and whether some achieve diabetes remission after stopping treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BGM0504, an experimental once-weekly injection, compared against semaglutide
What this could lead to
If BGM0504 outperforms semaglutide, it could offer a more effective option for managing blood sugar and weight, potentially leading to diabetes remission in early-stage patients.
What could go wrong
This is a phase 3 trial, but success is not guaranteed. BGM0504 may not prove superior to semaglutide, and side effects could limit its use. Results from this trial may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital(The Affiliated Hospital of Nanjing University Medical School)

    RECRUITING

    Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.